Eli Lilly: TRULICITY (dulaglutide)
FDA untitled letter, 19 January 2022. An Instagram video post for Trulicity said the drug lowers A1C but did not properly convey the indication or its limits. FDA said it showed risk information in small, fast-scrolling text and left out the hypoglycemia risk when used with insulin secretagogues or insulin.
The letter
- Date
- 19 January 2022
- Type
- Untitled letter (OPDP)
- Product
- BLA 125469 TRULICITY® (dulaglutide) injection, for subcutaneous use (BLA 125469)
- FDA matter number
- MA 1035
- Promoted piece
- Instagram post 'Trulicity 2020 Instagram Ad – 10,080 Minutes'
- Aimed at
- Consumers (DTC)
- Format
- Social media post
- Came in under Form FDA 2253
- Yes, the letter says it was submitted on Form FDA 2253
- Bad Ad Program
- The letter says FDA also received a complaint through the Bad Ad Program.
- Close-out
- FDA closed the matter out on 22 February 2022, 34 days after the letter.
Read the letter on FDA.gov · Promoted material (PDF) · Close-out letter
What FDA cited
The categories below are this tool's labels, read from the letter. Each quote is FDA's own wording, copied from the letter.
- Omits or minimizes risk
“By omitting this material information about this risk, the post creates a misleading impression about the drug’s safety.”
- Risk not clear and conspicuous
“the risk information is in a small window relegated to the bottom of the post and is presented using fast-paced, scrolling, small font that is difficult to read”
- Overstated or unsupported efficacy
“the suggestion that Trulicity will help “lower A1C” in all patients, when this has not been demonstrated.”
- Broader use than approved
“By failing to adequately communicate the indication and limitations of use associated with Trulicity, the post creates a misleading impression about the scope of the FDA-approved indication.”
Check your claims before FDA does
Arca reads a promotional piece against the approved labeling and the references it cites, and flags each claim the label does not support. See how Arca supports MLR review. Back to the OPDP letter search.